Group A and Group B Streptococcal Vaccine Development

Abstract
Over the last decade, tremendous progress has been made in the development of vaccines to prevent streptococcal diseases. The following summarizes the presentations of the round table at the International Lancefield Symposium in Paris. Dr. Kasper describes the most recent data from phase I clinical trials of conjugate group B polysaccharide vaccines. The remaining presentations outline five different strategies being used to develop group A streptococcal vaccines.